Abstract 1932P
Background
Local recurrence after radical surgery for retroperitoneal soft tissue sarcoma (RPS) occurs in 41–50% of patients and constitutes a major cause of death. CEB-01 is a biocompatible and biodegradable membrane implant with PLGA nanofibers entangled with SN-38 for a steady delivery. When placed in the surgical bed after RPS resection, it may increase local control rates and survival.
Methods
This is a multicentre, first in human trial (EudraCT: 2018-001026-25) following a 3+3 dose escalation design, and an expansion cohort at the recommended phase II dose (RP2D). Efficacy is evaluated using RECIST 1.1. Primary objective is RP2D. Safety, pharmacokinetics (PK) are secondary objectives.
Results
At present, 10 patients (pts) have been enrolled: 3 female / 7 male; mean age 62.1 years (40 - 77) with dedifferentiated liposarcoma (LPS) (5 cases), well differentiated LPS (3), LPS (1), and leiomyosarcoma (1). 7 pts had unresected primary lesions, and 3 were locoregional relapses. Post-surgery margins were R0 (7), R1 (2) and unknown (1). CEB-01 was implanted in 3 dose-increasing cohorts: 1st) 2 membranes of 180 cm2 each, 25 mcg/cm2, total 9 mg; 2nd) 2 x 180 cm2, 50 mcg/cm2, total 18 mg and 3rd) 4 x 180 cm2, 50 mcg/cm2, total 36 mg. No dose limiting toxicity (DLT) has been observed in any of the cohorts. The expansion phase is ongoing. Adverse events are similar to those post-surgery of RPS. Death (3 pts), after abdominal infection, bleeding (both unrelated) or retroperitoneal haemorrhage (related). After a median follow-up of 16.3 months (2.1 to 24.9), 2 (with the lower dose) local recurrences in the area of the implant have been observed after 5.5- and 8.6-months post-surgery. 2 pts completed 24 months of follow-up. In 5 ongoing pts no recurrences have been observed after 2.1 to 17.8 months of follow-up (median 16.2 months). SN-38’s PK shows dose linearity, half-life ranging from 287 - 372 hours, Cmax: 0.76 - 3.58 ng/ml and AUC 0-t: 118 - 321 ng/ml*h. Blood levels of SN-38 were detectable 28 days after surgery.
Conclusions
With CEB-01 no DLT has been observed. Local recurrence occurred in 2 out of 10 pts at 5.5- and 8.6-months post-surgery. CEB-01 provides a local steady and prolonged release of SN-38, with a much lower Cmax than when SN-38 is administered as irinotecan.
Clinical trial identification
NCT04619056.
Editorial acknowledgement
Legal entity responsible for the study
Cebiotex S.L.
Funding
Cebiotex S.L.
Disclosure
A. Perez Campos: Financial Interests, Personal, Advisory Board: Cebiotex. F. Cano Casas: Financial Interests, Personal, Stocks or ownership, shareholder of Cebiotex, S.L. through the society Cebfunding, S.L.: Cebiotex SL. J.A. Tornero García: Financial Interests, Personal, Stocks or ownership, shareholder: Cebiotex S.L.; Financial Interests, Personal, Leadership Role, CTO of Cebiotex, S. L.: Cebiotex S.L.. L. Marti: Financial Interests, Personal, Stocks or ownership, shareholder: Cebiotex. L. Krauel: Financial Interests, Personal, Leadership Role, CSO and cofounder: Cebiotex. All other authors have declared no conflicts of interest.
Resources from the same session
1940P - Deep molecular profiling of advanced synovial sarcoma as a basis for interventional clinical trials
Presenter: Richard Schlenk
Session: Poster session 15
1941P - Preliminary efficacy and safety of SHR-2554 in advanced epithelioid sarcoma: A phase II trial
Presenter: Haiyan Hu
Session: Poster session 15
1942P - Non-metastatic malignant phyllodes tumors of the breast (B-MPT): A retrospective analysis from a referral center
Presenter: Carmine Valenza
Session: Poster session 15
1944P - MAGE-A4 and NY-ESO-1 expression analysed in a synovial sarcoma tissue micro-array
Presenter: Lore De Cock
Session: Poster session 15
1945P - Diagnostic and therapeutic impact of liquid biopsy in soft tissue sarcomas: A case series
Presenter: Tarek Assi
Session: Poster session 15
1946P - Bladder primary sarcomas (BSar): A genomic landscape and clinical outcomes study
Presenter: ALINA BASNET
Session: Poster session 15
1947P - Predictors and outcomes of recurrent retroperitoneal liposarcoma: New insights into its recurrence patterns
Presenter: Huan Deng
Session: Poster session 15
1948P - Concordance of the pathological diagnosis between local institutional and central judgment in high-grade non-round-cell sarcomas: A supplementary analysis of JCOG1306
Presenter: Eisuke Kobayashi
Session: Poster session 15
1949P - Pegylated liposomal doxorubicin (PLD) combined with trabectedin as a treatment option in uterine sarcomas
Presenter: Laura Strobel
Session: Poster session 15